Pharmaceuticals, Biotechnology and Life Sciences
Allergan plc and Ironwood Pharmaceuticals, Inc. have announced that Allergan has acquired rights to Constella (linaclotide) in the European Union, Switzerland, Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to Linzess (linaclotide) in Mexico from Almirall.
Strensiq is the first treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP) approved approved by FDA.
Food and Drug Administration (FDA) has approved YONDELIS (trabectedin) for the treatment of patients with unresectable (unable to be removed…
Anavex Life Sciences Corp., has announced it would be trading its common stock on the NASDAQ, an American/Canadian stock exchange, one…
The U.S. Food and Drug Administration has approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat…
Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx(TM) (secukinumab)…
REFRESH OPTIVE Gel Drops, a new aqueous gel expertly designed for patients who need or desire a more viscous artificial tear option to relieve their Dry Eye symptoms.
The percentage of Americans who reported using marijuana in the past year more than doubled between 2001-2002 and 2012-2013, and the increase in marijuana use disorder during that time was nearly as large.
Dechra has announced that on the closing date of its Takeover Offer to acquire the shares in Genera not owned by…
The Substance Abuse and Mental Health Services Administration (SAMHSA), in conjunction with the Centers for Medicare & Medicaid Services (CMS) and the Assistant Secretary of Planning and Evaluation (ASPE), today awarded a total of $22.9 million to support states throughout the nation in their efforts to improve behavioral health of their citizens by providing community-based mental and substance use disorder treatment.